The Probiotic CFU Myth: What Billions of Bacteria Don't Tell You

The probiotic market is built on a number. That number tells you almost nothing.

Walk into any health food store. Every probiotic label competes on CFU — colony forming units. 10 billion. 50 billion. 100 billion. The implication is that more is better, and that a higher CFU count means a more effective product. The research says neither of those things is reliably true.

Here's why, and what actually matters.

What the research actually shows

A 2023 systematic review and meta-analysis by Goodoory et al. published in Gastroenterology — one of the most prestigious gastroenterology journals in the world — analysed 82 randomised controlled trials on probiotics in irritable bowel syndrome, involving over 10,000 patients. The findings are striking: different bacterial strains produced completely different outcomes for different symptoms. Lactobacillus plantarum 299V showed evidence for global symptom relief. Saccharomyces cerevisiae I-3856 showed low-certainty evidence for abdominal pain reduction. Bifidobacterium strains showed benefit for abdominal pain specifically. Combination products showed variable results depending on formulation.

The researchers found that certainty in the evidence varied dramatically by strain — and was low to very low for most categories. The critical point: two products could both contain “50 billion CFU” of different organisms and produce opposite outcomes for the same patient. CFU tells you quantity. It tells you nothing about which organism you're taking, whether it survives to the colon, or whether it's the strain with evidence for your specific concern.

A 2023 review by Roy and Dhaneshwar published in the World Journal of Gastroenterology examined the evidence for probiotics in inflammatory bowel disease and found that specific bacterial strains operate through distinct mechanisms: some produce antimicrobial compounds like bacteriocins, others modulate immune signalling through specific cytokine pathways, others enhance intestinal barrier function via tight junction proteins. The same gram of Lactobacillus doesn't automatically do all of these things. The species level matters. The strain level matters even more. Strain-level specificity in probiotic activity is not a marketing distinction — it's a biological reality.

The CFU survival problem

Here's the other thing most people don't know. The gastric environment has a pH of 1.5–3.5. Many probiotic strains in capsule form don't survive the journey from your stomach to the colon. The CFU count on the label reflects what's in the capsule at manufacture. What arrives in your large intestine — where it actually needs to work — can be dramatically lower.

Enteric coating helps. Spore-forming organisms (like Bacillus coagulans) have natural acid resistance. But a commodity capsule with a high CFU number and no information about survivability is not necessarily more effective than a lower-dose product with documented acid stability and strain-level evidence.

I built Milenium around live cultures in a sparkling drink format specifically because traditional fermented beverages have been delivering live microorganisms to the gut for thousands of years. The live culture environment of a probiotic drink — with its natural buffering from organic acids, natural pH, and minimal processing — is inherently different from a dry-compressed capsule sitting on a shelf for 18 months. That doesn't make capsules ineffective. But it does mean the delivery matrix is part of the formula, not just the organism inside it.

What to actually look for

Stop leading with CFU count. Start asking four questions instead.

First: What is the strain? Not just Lactobacillus acidophilus — which strain? L. acidophilus NCFM and L. acidophilus La-5 are different organisms with different evidence bases. If a product lists the genus and species but not the strain, you don't know what you're buying.

Second: Is there human clinical evidence for that specific strain and your specific concern? Strain X shown to reduce antibiotic-associated diarrhoea is not the same as strain X shown to improve IBS symptoms. They're different applications. Check whether the evidence matches your goal.

Third: Does the organism survive to the colon? Look for acid-resistant strains, enteric-coated delivery, or spore-forming organisms if survivability isn't otherwise established.

Fourth: Is the product handled and stored correctly? Many live cultures are temperature-sensitive. A probiotic capsule that was shipped and stored at room temperature for six months may have half the live organisms it started with, regardless of what the label says.

The biotype angle

Gut microbiome composition differs significantly by biotype — not perfectly, but the patterns are real. Endomorphs tend to show higher proportions of Firmicutes relative to Bacteroidetes, a ratio associated with more efficient caloric extraction from food. Ectomorphs often have faster gut transit and may benefit most from strains that specifically address colonisation time and barrier integrity. Mesomorphs with high training volumes have elevated gut permeability risk (as the colostrum data showed) and benefit from strains with specific barrier-supporting evidence.

One probiotic product doesn't serve all three biotypes equally. The right strain depends on the mechanism you need, which depends on your metabolic baseline. More CFUs won't fix a mismatch in strain selection.

Download the free Biotype Guide at milenium.com.au
→ milenium.com.au

References:
1. Goodoory VC et al. Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis. Gastroenterology, 2023. DOI: 10.1053/j.gastro.2023.07.018
2. Roy S, Dhaneshwar S. Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease. World Journal of Gastroenterology, 2023. DOI: 10.3748/wjg.v29.i14.2078